US 11254731
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
granted A61KA61K48/0008A61K48/0058
Quick answer
US patent 11254731 (Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A) held by Takeda Pharmaceutical Company Limited expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K48/0008, A61K48/0058, A61K48/0066, A61P